📊 KLRS Key Takeaways
Is KLRS a Good Investment? Thesis Analysis
Kalaris is a development-stage biotech company with minimal revenue ($165K) and substantial operating losses (-$46.2M). While the company maintains a strong cash position ($98.1M) with zero debt, the current burn rate of $38.4M annually provides only ~2.5 years of operational runway without reaching meaningful revenue generation. Absent evidence of near-term commercialization or milestone achievement, the risk-reward profile is heavily skewed toward execution failure.
Why Buy KLRS? Key Strengths
- Strong liquidity position with $98.1M cash and 12.23x current ratio
- Zero debt, clean balance sheet with manageable liabilities
- Improving operational efficiency trend with EPS improving 94.5% YoY despite losses
KLRS Investment Risks to Consider
- Pre-revenue stage with only $165K annual revenue and -$46.2M operating loss
- Negative operating cash flow of -$38.4M indicates unsustainable burn rate and limited runway
- High-risk biotech sector with significant clinical, regulatory, and commercial execution risk
- No evidence of near-term revenue inflection or commercialization milestones from available data
Key Metrics to Watch
- Operating cash burn rate and remaining cash runway
- Clinical trial progress and FDA milestone achievements
- Quarterly revenue growth trajectory and commercialization timeline
KLRS Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 12.23x current ratio provides a solid financial cushion.
KLRS Profitability Ratios
KLRS vs Healthcare Sector
How Kalaris Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is KLRS Overvalued or Undervalued?
Based on fundamental analysis, Kalaris Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
KLRS Balance Sheet & Liquidity
KLRS 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Kalaris Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-51.77 indicates the company is currently unprofitable.
KLRS Growth Metrics (YoY)
KLRS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | $165.0K | -$2.5M | N/A |
| Q2 2020 | $165.0K | -$2.5M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
KLRS Capital Allocation
KLRS SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Kalaris Therapeutics, Inc. (CIK: 0001754068)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KLRS
What is the AI rating for KLRS?
Kalaris Therapeutics, Inc. (KLRS) has an AI rating of SELL with 58% confidence, based on fundamental analysis of SEC EDGAR filings.
What are KLRS's key strengths?
Claude: Strong liquidity position with $98.1M cash and 12.23x current ratio. Zero debt, clean balance sheet with manageable liabilities.
What are the risks of investing in KLRS?
Claude: Pre-revenue stage with only $165K annual revenue and -$46.2M operating loss. Negative operating cash flow of -$38.4M indicates unsustainable burn rate and limited runway.
What is KLRS's revenue and growth?
Kalaris Therapeutics, Inc. reported revenue of $165.0K.
Does KLRS pay dividends?
Kalaris Therapeutics, Inc. does not currently pay dividends.
Where can I find KLRS SEC filings?
Official SEC filings for Kalaris Therapeutics, Inc. (CIK: 0001754068) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KLRS's EPS?
Kalaris Therapeutics, Inc. has a diluted EPS of $-2.85.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KLRS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Kalaris Therapeutics, Inc. has a SELL rating with 58% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KLRS stock overvalued or undervalued?
Valuation metrics for KLRS: ROE of -55.1% (sector avg: 15%), net margin of -26,326.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KLRS stock in 2026?
Our dual AI analysis gives Kalaris Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KLRS's free cash flow?
Kalaris Therapeutics, Inc.'s operating cash flow is $-38.4M, with capital expenditures of $200.0K. FCF margin is -23,375.8%.
How does KLRS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -26,326.1% (avg: 12%), ROE -55.1% (avg: 15%), current ratio 12.23 (avg: 2).